Register Login
Register to leave comments
  • News bot April 27, 2026, 11:05 a.m.

    📋 ETON PHARMACEUTICALS, INC. (ETON) - Clinical Trial Update

    Filing Date: 2026-04-27

    Accepted: 2026-04-27 07:05:10

    Event Type: Clinical Trial Update

    Event Details:

    ETON PHARMACEUTICALS, INC. (ETON) Announces Clinical Trial Update ETON PHARMACEUTICALS, INC. (ETON) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: study, expected
    • Diseases/Conditions: rare diseases, more convenient
    • Clinical Stage: clinical study, Clinical Study
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: Eton Pharmaceuticals
      • anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793
      • expected in the second half of 2026

    🔬 Clinical Development Pipeline (ETON PHARMACEUTICALS, INC.):

    Product Type Development Stage Therapeutic Area Source
    TRC093 recombinant humanized IgG1k monoclonal antibody DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    TRC102 + pemetrexed DRUG Phase PHASE1 Neoplasm ClinicalTrials.gov
    TRC105 chimeric anti-CD105 antibody DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Chronic Obstructive Pulmonary Disease ClinicalTrials.gov
    TRN-157 DRUG Phase PHASE1 Chronic Obstructive Pulmonary Disease ClinicalTrials.gov
    Tiotropium DRUG Phase PHASE2 Asthma ClinicalTrials.gov
    TRC105 and Bevacizumab DRUG Phase PHASE1 Adult Solid Tumor ClinicalTrials.gov
    Capecitabine DRUG Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    TRC105 DRUG Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    Bevacizumab BIOLOGICAL Phase PHASE2 Choriocarcinoma ClinicalTrials.gov
    Votrient DRUG Phase PHASE3 Advanced Angiosarcoma ClinicalTrials.gov
    TRC105 and Pazopanib DRUG Phase PHASE1 Advanced Soft Tissue Sarcoma ClinicalTrials.gov
    OPDIVO DRUG Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Carotuximab (TRC105) DRUG Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Sorafenib DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Axitinib DRUG Phase PHASE1 Renal Cell Carcinoma ClinicalTrials.gov
    TRC105 and Axitinib DRUG Phase PHASE1 Renal Cell Carcinoma ClinicalTrials.gov
    TRC253 DRUG Phase PHASE1 Metastatic Castrate-resistant Prostate Cancer ClinicalTrials.gov
    Atezolizumab DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    TJ004309 DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Cemiplimab BIOLOGICAL Phase PHASE1 Oncology ClinicalTrials.gov
    E-602 BIOLOGICAL Phase PHASE1 Oncology ClinicalTrials.gov
    Matching placebo control DRUG Phase PHASE2 Uncontrolled Hypertension ClinicalTrials.gov
    RTN-001 DRUG Phase PHASE2 Uncontrolled Hypertension ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ETON PHARMACEUTICALS, INC.
    • Ticker Symbol: ETON

Search

News categories